Treprostinil, non-comp unit
Products billed under this code include Tyvaso.
Payment limit per 1.74 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Tyvaso.
Payment limit per 1.74 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tyvaso | United Therapeutics Corporation | 66302-0206-01 | 28 | $23,250.724 |
| Tyvaso | United Therapeutics Corporation | 66302-0206-02 | 28 | $23,250.724 |
| Tyvaso | United Therapeutics Corporation | 66302-0206-03 | 4 | $3,321.532 |
| Tyvaso | United Therapeutics Corporation | 66302-0206-04 | 4 | $3,321.532 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $830.383 | −$2.444 | 1.74 MG | Treprostinil, non-comp unit | v1, posted September 17, 2026 |
| 3Q26 | $832.827 | +$43.65 | 1.74 MG | Treprostinil, non-comp unit | v1, posted September 15, 2026 |
| 2Q26 | $789.177 | −$2.804 | 1.74 MG | Treprostinil, non-comp unit | v1, posted September 15, 2026 |
| 1Q26 | $791.981 | −$4.112 | 1.74 MG | Treprostinil, non-comp unit | v1, posted September 15, 2026 |
| 4Q25 | $796.093 | −$4.06 | 1.74 MG | Treprostinil, non-comp unit | v1, posted September 8, 2026 |
| 3Q25 | $800.153 | +$39.758 | 1.74 MG | Treprostinil, non-comp unit | v1, posted March 10, 2026 |
| 2Q25 | $760.395 | +$0.243 | 1.74 MG | Treprostinil, non-comp unit | v1, posted March 10, 2026 |
| 1Q25 | $760.152 | −$0.083 | 1.74 MG | Treprostinil, non-comp unit | v1, posted December 19, 2025 |
| 4Q24 | $760.235 | +$0.367 | 1.74 MG | Treprostinil, non-comp unit | v1, posted June 11, 2025 |
| 3Q24 | $759.868 | +$34.602 | 1.74 MG | Treprostinil, non-comp unit | v1, posted June 11, 2025 |
| 2Q24 | $725.266 | −$5.054 | 1.74 MG | Treprostinil, non-comp unit | v1, posted March 11, 2025 |
| 1Q24 | $730.32 | −$3.318 | 1.74 MG | Treprostinil, non-comp unit | v1, posted December 19, 2024 |
| 4Q23 | $733.638 | −$3.738 | 1.74 MG | Treprostinil, non-comp unit | v1, posted October 10, 2024 |
| 3Q23 | $737.376 | −$1.771 | 1.74 MG | Treprostinil, non-comp unit | v1, posted June 5, 2024 |
| 2Q23 | $739.147 | +$34.497 | 1.74 MG | Treprostinil, non-comp unit | v1, posted February 23, 2024 |
| 1Q23 | $704.65 | +$0.006 | 1.74 MG | Treprostinil, non-comp unit | v1, posted December 6, 2023 |
| 4Q22 | $704.644 | +$0.01 | 1.74 MG | Treprostinil, non-comp unit | v1, posted June 22, 2023 |
| 3Q22 | $704.634 | +$0.256 | 1.74 MG | Treprostinil, non-comp unit | v1, posted June 9, 2023 |
| 2Q22 | $704.378 | +$33.303 | 1.74 MG | Treprostinil, non-comp unit | v1, posted December 14, 2022 |
| 1Q22 | $671.075 | +$0.128 | 1.74 MG | Treprostinil, non-comp unit | v1, posted June 8, 2022 |
| 4Q21 | $670.947 | +$0.049 | 1.74 MG | Treprostinil, non-comp unit | v1, posted June 2, 2022 |
| 3Q21 | $670.898 | −$0.409 | 1.74 MG | Treprostinil, non-comp unit | v1, posted June 2, 2022 |
| 2Q21 | $671.307 | −$0.528 | 1.74 MG | Treprostinil, non-comp unit | v1, posted March 1, 2022 |
| 1Q21 | $671.835 | – | 1.74 MG | Treprostinil, non-comp unit | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.